Failed in phase 2
Amiloride: protect nerve tissue in relapsing MS
relapsing MS · Axonal protection / ion channels / excitotoxicity
Controlled phase 2 trials did not meet their main goal for this group.
- Trials
- 1
- Running now
- 0
- Controlled phase 2/3 trials
- 1
- People in controlled trials
- 46
How the verdict was reached
Negative in phase 2
| Trial | Phase | Participants | Started | Result | Counted |
|---|---|---|---|---|---|
| ACTION | Phase 2 | 46 | 2013 | Missed its main goal No significant differences were found in GDx ( p = 0.840). Paper abstract | Counted |
Counted: 1. Will count later: 0. Not counted: 0.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- Oct 2026Status changed from Results pending to Failed in phase 2
- Oct 2026First listed as Results pending
Related hypotheses
Assembled by software from public sources.